agilon health(US:AGL) Prnewswire·2026-02-06 13:46Core Viewpoint - The complaint against agilon health alleges that the company and its executives violated federal securities laws by making false or misleading statements and failing to disclose significant risks related to their 2025 guidance and financial impacts from strategic actions taken to reduce risk [2]. Group 1 - The complaint claims that the defendants recklessly issued guidance for 2025, which they knew or should have known was unattainable due to material industry headwinds [2]. - It is alleged that the defendants materially overstated the immediate positive financial impact from strategic actions taken by agilon to mitigate risk [2]. - As a result of these actions, the statements made by the defendants regarding agilon's business, operations, and prospects were materially false and misleading at all times [2]. Group 2 - The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class, who directs and oversees the litigation on behalf of the putative class [3]. - Any member of the putative class has the option to move the Court to serve as lead plaintiff or may choose to remain an absent class member without affecting their ability to share in any recovery [3]. Group 3 - Faruqi & Faruqi, LLP encourages individuals with information regarding agilon health's conduct to contact the firm, including whistleblowers and former employees [4].